GRI Bio, Inc. (GRI)

Market Cap	2.93M +106.8%
Revenue (ttm)	n/a
Net Income	-10.91M
EPS	-27.02
Shares Out	1.45M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	22,255
Open	2.140
Previous Close	2.150
Day's Range	2.030 - 2.157
52-Week Range	2.030 - 80.360
Beta	-0.77
Analysts	Strong Buy
Price Target	25.00 (+1,131.53%)
Earnings Date	May 14, 2026

About GRI

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 4
• Stock Exchange: NASDAQ
• Ticker Symbol: GRI
• Website: https://www.gribio.com

Analyst Summary

According to 2 analysts, the average rating for GRI stock is "Strong Buy." The 12-month stock price target is $25.0, which is an increase of 1,131.53% from the latest price.

Price Target

$25.0

(1,131.53% upside)

Analyst Consensus: Strong Buy